BOURLA ALBERT

Albert Bourla's Form 4 record at Pfizer runs 423 transactions from February 2014 through July 2026, and it is a single-issuer record — no other company appears anywhere in his filing history. The most recent 25 transactions shown here, stretching from June 2025 through July 2026, are uniformly code-A acquisitions: a recurring twice-monthly pattern of roughly 21 to 26 shares each, priced (where a price is listed) between $23.29 and $26.43. That steady small cadence is dwarfed once by a single filing on 2026-03-03 recording an acquisition of 708,666 shares at $26.58 — more than 800 times the size of the routine grants surrounding it, and the only outlier in an otherwise uniform run.

None of the twenty-five most recent transactions carries a sale code, which sits in contrast with the lifetime total: 2,560,623 shares sold across the full 2014-2026 record against zero recorded open-market purchases. The recent stretch shown here is entirely on the acquisition side of the ledger — the large sales that built the 2.56-million-share lifetime total sit earlier in the record, outside this most-recent window.